Latest common stock for ZYME: $1.1T.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
Zymeworks BC (ZYME) currently reports a common stock of $1.1T as of March 2026. That compares with $1B in the prior-year period — up 109454.6% year over year. Use the charts on this page to explore Zymeworks BC's common stock history and peer comparisons.
Zymeworks BC's common stock increased from $1B to $1.1T — a 109454.6% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Zymeworks BC reported $1.1T in common stock as of March 2026. That compares with $1B in the prior-year period — up 109454.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current common stock of $1.1T, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zymeworks BC, and consider following ZYME for alerts when major investors trade the stock.
Zymeworks BC is classified in the Healthcare sector. On common stock, it currently shows $1.1T. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZYME with unrelated industries.